Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5607-5612

  Hu, Zhangyong ^a   Zhou, Zhipeng ^a   Xiong, Guolian ^b   Wang, Yali ^b   Lai, Yi ^b   Deng, Lan ^b   Yang, Jinliang ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

Case control study; Cyclin D1; Hepatocellular carcinoma; Polymorphism

Indexed keywords

CYCLIN D1; HEPATITIS B SURFACE ANTIGEN;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER RISK; CHINESE; CONTROLLED STUDY; CYCLIN D1 GENE; DNA SEQUENCE; FEMALE; GENE; GENETIC RISK; GENOTYPE; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VIRUS CARCINOGENESIS; WILD TYPE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CYCLIN D1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK;

EID: 84904746651     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1741-3     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047-63.
4. Chen CJ, Chen DS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology. 2002;36:1046-9.
5. Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 2002; 35 (5 Suppl.2): S79-85. (Pubitemid 35278645)
6. Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005;42:846-53. (Pubitemid 41401122)
7. Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005;48:10-5. (Pubitemid 40529205)
8. Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans. 2010;38:217-22.
9. Callender T, El-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer. 1994;74:152-8. (Pubitemid 24187623)
10. Palmqvist R, Stenling R, Oberg A, Landberg G. Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer. 1998;34:1575-81. (Pubitemid 28446340)
11. Marsh KL, Varley JM. Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry. Br J Cancer. 1998;77:1460-8. (Pubitemid 28190746)
12. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558-72.
13. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005-11.
14. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620-8.
15. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 2003;278:30339-47. (Pubitemid 36962428)
16. Le Marchand L, Seifried A, Lum-Jones A, Donlon T, Wilkens LR. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. J Am Med Assoc. 2003;290:2843-8. (Pubitemid 37509493)
17. Zheng Y, Shen H, Sturgis EM, et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis. 2001;22:1195-9. (Pubitemid 32737335)
18. Wang L, Habuchi T, Takahashi T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257-64. (Pubitemid 34224000)
19. Wang L, Habuchi T, Mitsumori K, et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer. 2003;103:116-20. (Pubitemid 35424214)
20. Akkiz H, Bayram S, Bekar A, Akgöllü E, Ozdil B. Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol. 2010;34:298-302.
21. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266:1821-8.
22. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-7.
23. Donnellan R, Chetty R. Function of a human cyclin gene as an oncogene. Mol Pathol. 1998;51:1-7. (Pubitemid 28157349)
24. Zhang YJ, Jiang W, Chen CJ, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993;196:1010-6. (Pubitemid 23337708)
25. Nishida N, Fukuda Y, Komeda T, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994;54:3107-10. (Pubitemid 24208910)
26. Comstock CE, Augello MA, Benito RP, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res. 2009;15:5338-49.
27. Yu J, Habuchi T, Tsuchiya N, et al. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol. 2004;172:2410-3. (Pubitemid 39507545)
28. Krippl P, Langsenlehner U, Renner W, et al. The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat. 2003;82:165-8. (Pubitemid 37521972)
29. Yu C, Lu W, Tan W, et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2003;12:176. (Pubitemid 36194012)
30. Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729-34. (Pubitemid 38618524)
31. Zhang YJ, Chen SY, Chen CJ, Santella RM. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog. 2002;33:125-9. (Pubitemid 34113201)
32. Wang X, Zhang X, Qiu B, et al. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172-8.
33. Buch S, Zhu B, Davis AG, et al. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog. 2005;42:222-8.
34. Bala S, Peltomäki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 2001;61:6042-5. (Pubitemid 32762536)
35. Holley SL, Parkes G, Matthias C, et al. Cyclin D1 polymorphismand expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol. 2001;159:1917-24. (Pubitemid 33062533)